{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04275024",
      "OrgStudyIdInfo": {
        "OrgStudyId": "S2016-05-02"
      },
      "Organization": {
        "OrgFullName": "Guangdong Provincial Hospital of Traditional Chinese Medicine",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients",
      "OfficialTitle": "Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Patients With Moderate to Severe Psoriasis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2021",
      "OverallStatus": "Enrolling by invitation",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "April 1, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 24, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 24, 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "February 16, 2020",
      "StudyFirstSubmitQCDate": "February 16, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 19, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "March 3, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 4, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Chuanjian Lu",
        "ResponsiblePartyInvestigatorTitle": "Professor",
        "ResponsiblePartyInvestigatorAffiliation": "Guangdong Provincial Hospital of Traditional Chinese Medicine"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Guangdong Provincial Hospital of Traditional Chinese Medicine",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the efficacy and safety of Adipose derived Mesenchymal Stem Cells (AD-MSCs) plus Calpocitriol Ointment and PSORI-CM01 Granule with moderate to severe psoriasis. Any adverse events related to AD-MSCs infusion will be monitored.The primary outcome is the reduction rate of PASI(Psoriasis Area and Severity Index) and treatment response will be computed from PASI before and after treatment.",
      "DetailedDescription": "The purpose of this study is to evaluate the efficacy and safety of Adipose derived Mesenchymal Stem Cells (AD-MSCs) plus Calpocitriol Ointment and PSORI-CM01 Granule with moderate to severe psoriasis. Any adverse events related to AD-MSCs infusion will be monitored.The primary outcome is the reduction rate of PASI(Psoriasis Area and Severity Index) and treatment response will be computed from PASI before and after treatment."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Mesenchymal Stromal Cells",
          "Psoriasis",
          "Drug Effect",
          "Drug Toxicity"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "8",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Experimental group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.\n\nThe basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Calcipotriol ointment",
                "Drug: PSORI-CM01 Granule",
                "Biological: adipose-derived multipotent mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Calcipotriol ointment",
            "InterventionDescription": "The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Experimental group"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Dovonex"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "PSORI-CM01 Granule",
            "InterventionDescription": "PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Experimental group"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Chinese Herbal Medicine"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "adipose-derived multipotent mesenchymal stem cells",
            "InterventionDescription": "AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Experimental group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "PASI score improvement rate",
            "PrimaryOutcomeDescription": "PASI score improvement rate = (PASI score before intervention - PASI score after intervention)/PASI score before intervention Ã—100%",
            "PrimaryOutcomeTimeFrame": "12 weeks (plus or minus 3 days) after treatment"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "PASI(Psoriasis Area and Severity Index)",
            "SecondaryOutcomeDescription": "The improvement in PASI score from baseline after treatment",
            "SecondaryOutcomeTimeFrame": "12 weeks (plus or minus 3 days) after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "PASI-50",
            "SecondaryOutcomeDescription": "The proportion of patients who achieve at least 50% improvement in PASI score from baseline",
            "SecondaryOutcomeTimeFrame": "12 weeks (plus or minus 3 days) after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "PASI-75",
            "SecondaryOutcomeDescription": "The proportion of patients who achieve at least 75% improvement in PASI score from baseline",
            "SecondaryOutcomeTimeFrame": "12 weeks (plus or minus 3 days) after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Pruritus Scores on the Visual Analogue Scale",
            "SecondaryOutcomeDescription": "Pruritus was assessed using the Visual Analogue Scales; The Scale scores ranged from 0-10. The higer the scores were, the more itching the patient suffered",
            "SecondaryOutcomeTimeFrame": "12 weeks (plus or minus 3 days) after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "BSA",
            "SecondaryOutcomeDescription": "the Body Surface Area",
            "SecondaryOutcomeTimeFrame": "12 weeks (plus or minus 3 days) after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "DLQI(Dermatology Life Quality Index)",
            "SecondaryOutcomeDescription": "the Dermatology Life Quality Index",
            "SecondaryOutcomeTimeFrame": "12 weeks (plus or minus 3 days) after treatment"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nmoderate to severe psoriasis vulgaris ( PASI > 10 or BSA >10%)\n18 to 65 years old\nwritten/signed informed consent\n\nExclusion Criteria:\n\nguttate psoriasis, inverse psoriasis or exclusively associated with the face\nAcute progressive psoriasis, and erythroderma tendency\ncurrent (or within 1 year) pregnancy or lactation\ncurrent significant anxiety or depression with the Self-rating Anxiety Scale (SAS) > 50 or the Self-rating Depression Scale (SDS) > 53, or with other psychiatric disorders\nWith history of primary cardiovascular, respiratory, digestive, urinary, endocrinologic and hematologic diseases, which can't be controlled through ordinary treatments. Those who with malignant diseases, infections, electrolyte imbalance, acid-base disturbance. Patients with clinical test results listed below: abnormal serum calcium level ( Ca2+ > 2.9 mmol/L or < 2 mmol/L);AST or ALT 2 times more than normal upper limit; Creatinine and cystatin C more than normal upper limit; Hemoglobin elevates 20g/L more than normal upper limit,or hemoglobin reduction to anemia; Platelet count less than 75.0*10^9/L; White blood cell less than 3.0*10^9/L; Or any other abnormal laboratory test results, assessed by investigators, that are not suitable for this clinical study\nPatients with malignant tumors, or when they were enrolled with abnormal tumor markers or with other organ dysfunction\nallergy to anything else ever before;\ncurrent registration in other clinical trials or participation within a month;\ntopical treatments (i.e. corticosteroids or retinoic acid or Vitamin D analogs ) within 2 weeks; systemic therapy or phototherapy (ultraviolet radiation B,UVB) and psoralen combined with ultraviolet A (PUVA) within 4 weeks; biological therapy within 12 weeks;\nmedical conditions assessed by investigators, that are not suitable for this clinical study.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Chuanjian Lu, PhD",
            "OverallOfficialAffiliation": "Guangdong Provincial Hospital of Traditional Chinese Medicine",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Guangdong Provincial Hospital of Traditional Chinese Medicine",
            "LocationCity": "Guangzhou",
            "LocationState": "Guangdong",
            "LocationCountry": "China"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000011565",
            "ConditionMeshTerm": "Psoriasis"
          },
          {
            "ConditionMeshId": "D000064420",
            "ConditionMeshTerm": "Drug-Related Side Effects and Adverse Reactions"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000017444",
            "ConditionAncestorTerm": "Skin Diseases, Papulosquamous"
          },
          {
            "ConditionAncestorId": "D000012871",
            "ConditionAncestorTerm": "Skin Diseases"
          },
          {
            "ConditionAncestorId": "D000064419",
            "ConditionAncestorTerm": "Chemically-Induced Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M13574",
            "ConditionBrowseLeafName": "Psoriasis",
            "ConditionBrowseLeafAsFound": "Psoriasis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M29456",
            "ConditionBrowseLeafName": "Drug-Related Side Effects and Adverse Reactions",
            "ConditionBrowseLeafAsFound": "Drug Toxicity",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14826",
            "ConditionBrowseLeafName": "Skin Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18865",
            "ConditionBrowseLeafName": "Skin Diseases, Papulosquamous",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M29455",
            "ConditionBrowseLeafName": "Chemically-Induced Disorders",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC25",
            "ConditionBrowseBranchName": "Substance Related Disorders"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "C000055085",
            "InterventionMeshTerm": "Calcipotriene"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000003879",
            "InterventionAncestorTerm": "Dermatologic Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M347448",
            "InterventionBrowseLeafName": "Calcipotriene",
            "InterventionBrowseLeafAsFound": "Hydroxide",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M6226",
            "InterventionBrowseLeafName": "Dermatologic Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}